Clozapine is the gold-standard therapy for resistant schizophrenia. However, its use is limited by risks such as clozapine-induced agranulocytosis (CIA) and neutropenia (CIN), requiring strict monitoring. This study aimed to estimate the prevalence and mortality of CIA and CIN at GHU Paris Psychiatrie & Neurosciences and identify risk factors.
Methods:
This retrospective study used data from the health data warehouse. We selected all patients treated with clozapine between January 1, 2019, and December 31, 2024. Based on the absolute neutrophil count (ANC), we identified cases of CIA (ANC < 500/mm3) and CIN, classified as mild (ANC = (1000–1499/mm3)) or moderate (ANC = (500–999/mm3)). We then investigated risk factors using ordinal adjacent categories regression.
Results:
Among 1768 patients treated with clozapine, we identified 5 cases of CIA (prevalence: 0.28%), with no fatalities, and 163 cases of CIN (prevalence: 9.22%), including 36 moderate cases. African origins increased the risk of mild neutropenia (OR: 2.617; 95% CI: 1.327–5.163), while a higher ANC before treatment introduction decreased the risk (OR: 0.352; 95% CI: 0.229–0.542). Regarding the progression from mild to moderate neutropenia, receiving an anxiolytic treatment and being older than 49 years old significantly decreased the risk (OR: 0.189, 95% CI: 0.042–0.86; OR: 0.139, 95% CI: 025–0.772, respectively). Treatment was discontinued in 44% of the patients with neutropenia, and 53% were rechallenged with clozapine.
Conclusion:
Our study provides further evidence that CIA is a rare side effect. Given the benefits of clozapine and the rarity of agranulocytosis, our results suggest a looser approach to hematological monitoring and support the new French and US guidelines.
AgidOArenovichTSajeevG, et al. (2011) An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis. The Journal of Clinical Psychiatry72(11): 1439–1444.
2.
AlvirJMLiebermanJASaffermanAZ, et al. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. The New England Journal of Medicine329(3): 162–167.
BaldaMVGarayOUPapaleRM, et al. (2015) Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). International Clinical Psychopharmacology30(2): 109–114.
5.
BarnesTRDrakeRPatonC, et al. (2020) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England)34(1): 3–78.
6.
ButlerEStratfordMJauharS (2025) Should clozapine be offered as a second-line antipsychotic?The Lancet Psychiatry12(2): 85–86.
CooperJ-PChuePSirakiAG, et al. (2025) Predicting clozapine-induced adverse drug reaction biomarkers using machine learning. Scientific Reports15(1): 25572.
9.
CorrellCU (2025) Clozapine: Past, present and future. World Psychiatry24(2): 153–154.
10.
de LeonJ (2026) Prescribing clozapine to 10% of patients with schizophrenia may save 320,000 lives and cost 2400 deaths from agranulocytosis. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology104: 112747.
11.
EfthimiouOTaipaleHRaduaJ, et al. (2024) Efficacy and effectiveness of antipsychotics in schizophrenia: Network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet. Psychiatry11(2): 102–111.
12.
GeeSVergunstFHowesO, et al. (2014) Practitioner attitudes to clozapine initiation. Acta Psychiatrica Scandinavica130(1): 16–24.
13.
GirardinFRPoncetABlondonM, et al. (2014) Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: A cost-effectiveness analysis. The Lancet Psychiatry1(1): 55–62.
14.
GörenJLRoseAJSmithEG, et al. (2016) The business case for expanded clozapine utilization. Psychiatric Services (Washington, D.C.)67(11): 1197–1205.
15.
HsiehMMEverhartJEByrd-HoltDD, et al. (2007) Prevalence of neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. Annals of Internal Medicine146(7): 486–492.
16.
IngimarssonOMacCabeJHHaraldssonM, et al. (2016) Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: An observational study in Iceland. BMC Psychiatry16(1): 441.
17.
IslamFHainDLewisD, et al. (2022) Pharmacogenomics of clozapine-induced agranulocytosis: A systematic review and meta-analysis. The Pharmacogenomics Journal22(4): 230–240.
JohannsenC-FPetersenTSNielsenJ, et al. (2022) Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: A retrospective cohort study. Therapeutic Advances in Psychopharmacology12: 20451253211072341.
20.
JohnAPKoEKFDominicA (2018) Delayed initiation of clozapine continues to be a substantial clinical concern. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie63(8): 526–531.
21.
KaneJMAgidOBaldwinML, et al. (2019) Clinical guidance on the identification and management of treatment-resistant schizophrenia. The Journal of Clinical Psychiatry80(2): 18com12123.
22.
KeepersGAFochtmannLJAnziaJM, et al. (2020) The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. The American Journal of Psychiatry177(9): 868–872.
23.
KellyDLDixonLBKreyenbuhlJA, et al. (2006) Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. The Journal of Clinical Psychiatry67(9): 1404–1411.
24.
KellyDLKreyenbuhlJDixonL, et al. (2007) Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophrenia Bulletin33(5): 1221–1224.
25.
KellyDLGlassmanMWonodiI, et al. (2024) Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial. Schizophrenia Research268: 312–322.
26.
LawCSeeYMYeeJY, et al. (2023) The impact of clozapine delay on clinical outcomes in schizophrenia. The Journal of Clinical Psychiatry84(5): 22m14588.
27.
LeggeSEWaltersJT (2019) Genetics of clozapine-associated neutropenia: Recent advances, challenges and future perspective. Pharmacogenomics20(4): 279–290.
28.
LiX-HZhongX-MLuL, et al. (2020) The prevalence of agranulocytosis and related death in clozapine-treated patients: A comprehensive meta-analysis of observational studies. Psychological Medicine50(4): 583–594.
29.
MagistriCMelliniC (2023) Clozapine-associated agranulocytosis: A systematic review. Is it really so frighteningly common?Journal of Clinical Psychopharmacology43(6): 527.
30.
MalikSLallyJAjnakinaO, et al. (2018) Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research195: 267–273.
31.
MerzLEAchebeM (2021) When non-whiteness becomes a condition. Blood137(1): 13–15.
32.
MylesNMylesHXiaS, et al. (2018) Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatrica Scandinavica138(2): 101–109.
33.
MylesNMylesHXiaS, et al. (2019) A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. The Australian and New Zealand Journal of Psychiatry53(5): 403–412.
34.
NinomiyaKSaitoTIkedaM, et al. (2022) Pharmacogenomic-guided clozapine administration based on HLA-DQB1, HLA-B and SLCO1B3-SLCO1B7 variants: An effectiveness and cost-effectiveness analysis. Frontiers in Pharmacology13: 1016669.
35.
OloyedeEBlackmanGWhiskeyE, et al. (2022) Clozapine haematological monitoring for neutropenia: A global perspective. Epidemiology and Psychiatric Sciences31: e83.
36.
PazZNailsMZivE (2011) The genetics of benign neutropenia. The Israel Medical Association Journal: IMAJ13(10): 625–629.
37.
R Core Team (2021)R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. Available at: https://www.R-project.org
38.
R Core Team. (2025) R A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. - References - Scientific Research Publishing (n.d.). Available at: https://www.scirp.org/reference/referencespapers?referenceid=3967248 (accessed 23 August 2025).
39.
RahmanAMicanLMFischerC, et al. (2009) Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. The Annals of Pharmacotherapy43(5): 822–830.
40.
RappoportNSimonAJLevA, et al. (2015) Correlation between ‘ACKR1/DARC null’ polymorphism and benign neutropenia in Yemenite Jews. British Journal of Haematology170(6): 892–895.
41.
ReichDNallsMAKaoWHL, et al. (2009) Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genetics5(1): e1000360.
42.
RemingtonGAddingtonDHonerW, et al. (2017) Guidelines for the pharmacotherapy of schizophrenia in adults. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie62(9): 604–616.
43.
ResearchC (2025) Information on clozapine. U.S. Food and Drug Administration. Epub ahead of print 25 February 2025.
44.
ShahPIwataYPlitmanE, et al. (2018) The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Research268: 114–122.
45.
SinghBHughesAJRoerigJL (2020) Comfort level and barriers to the appropriate use of clozapine: A preliminary survey of US psychiatric residents. Academic Psychiatry: The Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry44(1): 53–58.
46.
SiskindDSiskindVKiselyS (2017) Clozapine response rates among people with treatment-resistant schizophrenia: Data from a systematic review and meta-analysis. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie62(11): 772–777.
47.
SiskindDNorthwoodKPillingerT, et al. (2025) Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: Consensus guidelines from a global Delphi panel. The Lancet Psychiatry13: 77–86.
48.
SiskindDNorthwoodKPillingerT, et al. (2026) Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: Consensus guidelines from a global Delphi panel. The Lancet Psychiatry13(1): 77–86.
49.
SkokouMKaraviaEADrakouZ, et al. (2022) Adverse drug reactions in relation to clozapine plasma levels: A systematic review. Pharmaceuticals (Basel, Switzerland)15(7): 817.
50.
SnowdonJHallidayG (2011) A study of the use of clozapine in old age psychiatry. International Clinical Psychopharmacology26(4): 232–235.
51.
SolmiMSeitidisGMavridisD, et al. (2023) Incidence, prevalence, and global burden of schizophrenia–data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry28(12): 5319–5327.
52.
StübnerSGrohmannREngelR, et al. (2004) Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry37: S70–S78.
53.
TaipaleHTanskanenAHowesO, et al. (2025) Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: A population-based cohort study. The Lancet. Psychiatry12(2): 122–130.
54.
ÜçokAÇikrikçiliUKarabulutS, et al. (2015) Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International Clinical Psychopharmacology30(5): 290–295.
55.
VermeulenJMvan RooijenGvan de KerkhofMPJ, et al. (2019) Clozapine and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophrenia Bulletin45(2): 315–329.
56.
YangC-CWangX-YChouP-H, et al. (2023) Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: A retrospective cohort study. BMC Psychiatry23: 170.
57.
YeeTW (2010) The VGAM package for categorical data analysis. Journal of Statistical Software32: 1–34.
58.
ZhouJZhouNLiuQ, et al. (2023) Prevalence of neutropenia in US residents: A population based analysis of NHANES 2011-2018. BMC Public Health23(1): 1254.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
